NCT04998058View on ClinicalTrials.gov

Autogenous Mesenchymal Stem Cell Culture-Derived Signalling Molecules as Enhancers of Bone Formation in Bone Grafting

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 15, 2025

Primary Completion Date

August 30, 2026

Study Completion Date

December 30, 2026

Conditions
Bone Loss, OsteoclasticBone Loss, AlveolarAlveolar Bone LossAlveolar Bone AtrophyGrafting Bone
Interventions
PROCEDURE

Maxillary sinus floor elevation grafting with synthetic bone substitute.

Bone augmentation at the floor of the maxillary sinus with bone substitutes.

Trial Locations (1)

90619-900

Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre

All Listed Sponsors
collaborator

ITI International Team for Implantology, Switzerland

OTHER

collaborator

KU Leuven

OTHER

collaborator

Rio Grande do Sul Brain Institute (InsCer)

UNKNOWN

lead

Pontificia Universidade Católica do Rio Grande do Sul

OTHER

NCT04998058 - Autogenous Mesenchymal Stem Cell Culture-Derived Signalling Molecules as Enhancers of Bone Formation in Bone Grafting | Biotech Hunter | Biotech Hunter